Ionis Pharmaceuticals — Jul 29, 2026 release

net product sales of $26 million and $42 million in the second quarter and first half of 2026, respectively; second quarter net product sales increased 63% compared to the first quarter of 2026   o On track to achieve full year 2026 product sales of $110-120 million, representing a continuing driver of year-over-year revenue growth   o Launch outside the U.S. underway, with new market approvals in the EU   2 • Zilganersen on track to launch this year as the first and only medicine to demonstrate clinically meaningful and disease-modifying benefit in children and adults with Alexander disease (AxD), assuming approval   o New Drug Application (NDA) under FDA Priority Review with PDUFA target action date of September 22, 2026   o Entered a license agreement with Recordati to develop and commercialize zilganersen outside the U.S.   • Obudanersen, a potential treatment for Angelman syndrome, completed enrollment in the Phase 3 REVEAL study, with data anticipated in the second half of 2027   • ION775, a potential treatment for sHTG, entered a Phase 2 study in people with sHTG and moderately elevated triglycerides (HTG) based on Phase 1 results showing robust triglyceride lowering with potential for extended dosing intervals   o Results from the Phase 1 study of ION775 will be presented